NEW QIAstat-Dx Respiratory 2019-nCoV Panel 

NEW QIAstat-Dx Respiratory 2019-nCoV Panel 

Molecular Diagnostics

December 18, 2020

To support the research efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN® developed the QIAstat-Dx® Respiratory 2019-nCoV Panel. This version of our multiplex syndromic cartridge detects and differentiates 22 respiratory targets, including 2019-nCoV (SARS-CoV-2).

  • Includes 2 molecular targets specific to 2019-nCoV: ORF1b gene recommended by the Chinese Center for Disease Control and Prevention, and the E gene recommended by the US Centers for Disease Control and Prevention
  • Less than 1 minute hands-on time
  • Time to result: approximately 1 hour
New TP53 MASTR

New TP53 MASTR

Molecular Diagnostics

Multiplicom is pleased to announce the release of the TP53 MASTR molecular assay for the identification of mutations in the entire coding region of TP53.




September 29, 2015 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us